Publications by authors named "Alfred H Moffett"
Background: Current treatment of vulvovaginal candidiasis (VVC) is largely limited to azole therapy. Ibrexafungerp is a first-in-class triterpenoid antifungal with broad-spectrum anti-Candida fungicidal activity. The objective of this study was to evaluate the efficacy and safety of ibrexafungerp compared with placebo in patients with acute VVC.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the impact of denosumab on bone density, mass, strength, and wrist fracture incidence in postmenopausal women with osteoporosis.
- Denosumab showed significant improvements in radius bone density and strength compared to placebo, with notable effects on both cortical and trabecular bone.
- Among higher-risk participants, denosumab reduced the incidence of wrist fractures significantly, indicating its potential as an effective treatment for osteoporosis-related fracture prevention.
Denosumab is an approved therapy for postmenopausal women with osteoporosis at high or increased risk for fracture. In the FREEDOM study, denosumab reduced fracture risk and increased bone mineral density (BMD). We report the spine and hip dual-energy X-ray absorptiometry (DXA) BMD responses from the overall study of 7808 women and from a substudy of 441 participants in which more extensive spine and hip assessments as well as additional skeletal sites were evaluated.
View Article and Find Full Text PDFBackground: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action.
Methods: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.